Drug combination studies and their synergy quantification using the Chou-Talalay method
- PMID: 20068163
- DOI: 10.1158/0008-5472.CAN-09-1947
Drug combination studies and their synergy quantification using the Chou-Talalay method
Abstract
This brief perspective article focuses on the most common errors and pitfalls, as well as the do's and don'ts in drug combination studies, in terms of experimental design, data acquisition, data interpretation, and computerized simulation. The Chou-Talalay method for drug combination is based on the median-effect equation, derived from the mass-action law principle, which is the unified theory that provides the common link between single entity and multiple entities, and first order and higher order dynamics. This general equation encompasses the Michaelis-Menten, Hill, Henderson-Hasselbalch, and Scatchard equations in biochemistry and biophysics. The resulting combination index (CI) theorem of Chou-Talalay offers quantitative definition for additive effect (CI = 1), synergism (CI < 1), and antagonism (CI > 1) in drug combinations. This theory also provides algorithms for automated computer simulation for synergism and/or antagonism at any effect and dose level, as shown in the CI plot and isobologram, respectively.
Comment in
-
Drug combination studies and their synergy quantification using the Chou-Talalay method--letter.Cancer Res. 2015 Jun 1;75(11):2400. doi: 10.1158/0008-5472.CAN-14-3763. Cancer Res. 2015. PMID: 25977339 No abstract available.
Similar articles
-
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.Pharmacol Rev. 2006 Sep;58(3):621-81. doi: 10.1124/pr.58.3.10. Pharmacol Rev. 2006. PMID: 16968952 Review.
-
Drug combination studies and their synergy quantification using the Chou-Talalay method--letter.Cancer Res. 2015 Jun 1;75(11):2400. doi: 10.1158/0008-5472.CAN-14-3763. Cancer Res. 2015. PMID: 25977339 No abstract available.
-
Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method.Am J Cancer Res. 2015 Dec 15;6(1):97-104. eCollection 2016. Am J Cancer Res. 2015. PMID: 27073727 Free PMC article.
-
The mass-action law based algorithms for quantitative econo-green bio-research.Integr Biol (Camb). 2011 May;3(5):548-59. doi: 10.1039/c0ib00130a. Epub 2011 Mar 14. Integr Biol (Camb). 2011. PMID: 21403972
-
Preclinical versus clinical drug combination studies.Leuk Lymphoma. 2008 Nov;49(11):2059-80. doi: 10.1080/10428190802353591. Leuk Lymphoma. 2008. PMID: 19021049 Review.
Cited by
-
Synergistic effects of bloom helicase (BLM) inhibitor AO/854 with cisplatin in prostate cancer.Sci Rep. 2024 Oct 23;14(1):24962. doi: 10.1038/s41598-024-75938-5. Sci Rep. 2024. PMID: 39438537 Free PMC article.
-
ML385, an Nrf2 Inhibitor, Synergically Enhanced Celastrol Triggered Endoplasmic Reticulum Stress in Lung Cancer Cells.ACS Omega. 2024 Oct 15;9(43):43697-43705. doi: 10.1021/acsomega.4c06152. eCollection 2024 Oct 29. ACS Omega. 2024. PMID: 39493971 Free PMC article.
-
Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.PLoS One. 2013 Jun 24;8(6):e66755. doi: 10.1371/journal.pone.0066755. Print 2013. PLoS One. 2013. PMID: 23826126 Free PMC article.
-
Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.Int J Oncol. 2015 Mar;46(3):963-72. doi: 10.3892/ijo.2014.2804. Epub 2014 Dec 19. Int J Oncol. 2015. PMID: 25530098 Free PMC article.
-
Prodigiosin-Functionalized Probiotic Ghosts as a Bioinspired Combination Against Colorectal Cancer Cells.Probiotics Antimicrob Proteins. 2023 Oct;15(5):1271-1286. doi: 10.1007/s12602-022-09980-y. Epub 2022 Aug 28. Probiotics Antimicrob Proteins. 2023. PMID: 36030493 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
